US · Healthcare · Drug Manufacturers - General
EPS came in at 2.63 against a street estimate of 2.50 — a beat of 5.2%.
Analysts rate AstraZeneca PLC a strong buy (9 buy, 1 hold, 0 sell out of 10) with an average price target of $213.69.
| Fund | Stake |
|---|---|
| Investors Finance Co PLC | 3.33% |
| Vanguard Capital Management, LLC | 2.90% |
| Capital Research & Mgmt Co - Division 3 | 2.22% |
| FMR Inc | 1.91% |
| Capital World Investors | 1.82% |
| Legal & General Group PLC | 1.67% |
| Wellington Management Company LLP | 1.53% |
| T. Rowe Price Associates, Inc. | 1.26% |
| Action | Detail | Date |
|---|---|---|
| Dividend | $1.06 / share ex-date Aug 7, 2026 · pay Sep 8, 2026 | 2026-08-07 |
| Dividend | $2.17 / share ex-date Feb 20, 2026 · pay Mar 23, 2026 | 2026-02-20 |
| Split | 1 : 2 effective Feb 2, 2026 | 2026-02-02 |
| Dividend | $1.03 / share ex-date Aug 8, 2025 · pay Sep 8, 2025 | 2025-08-08 |
Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for AstraZeneca PLC — free to start.
Google PlayApp StoreData updated 2026-08-05.